Register entryShortage reported
- Registered sites
- 11
- Active NDC listings
- 27
- Labeller names
- 3
- Live patents
- 174
- Exclusivities
- 8
- Shortage listings
- 82
- Countries
- 8
- Base
- United States
Authorisation
Registered operations
Analytical testing11Active ingredient (API) manufacture7Labelling4Finished drug manufacture4Packaging4
Sites
Registered establishments
11| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Pfizer Manufacturing Austria GmbHRegistrant: Pfizer Inc | Uferstrasse 15, Orth an der Donau, Niederosterreich 2304, Austria (AUT) | Analytical testing, Active ingredient (API) manufacture | 3011606091300453240 |
| Pfizer Manufacturing Belgium NVRegistrant: Pfizer Inc | Rijksweg 12, Puurs-Sint-Amands, 2870, Belgium (BEL) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 1000654629370156507 |
| Pfizer Manufacturing Deutschland GmbHRegistrant: Pfizer Inc | Mooswaldallee 1, Freiburg im Breisgau, BW 79108, Germany (DEU) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3002807097341970073 |
| Pfizer Ireland Pharmaceuticals Unlimited CompanyRegistrant: Pfizer Inc | RINGASKIDDY API PLANT, RINGASKIDDY, Co. Cork P43 X336, Ireland (IRL) | Analytical testing, Active ingredient (API) manufacture | 3002807852985052076 |
| Pfizer Italia S.r.l.Registrant: Pfizer Inc | Localita Marino Del Tronto, Ascoli Piceno, 63100, Italy (ITA) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3003637173458521908 |
| Pfizer Asia Manufacturing Pte LtdRegistrant: Pfizer Inc | 11 Tuas Bay Street, Singapore, 639164, Singapore (SGP) | Analytical testing, Active ingredient (API) manufacture | 3003901862936889401 |
| Pfizer Health ABRegistrant: Pfizer Inc | Mariefredsvagen 37, Strangnas, Sodermanland 645 41, Sweden (SWE) | Analytical testing, Active ingredient (API) manufacture | 3003150913354433591 |
| SEAGEN INC.Registrant: Pfizer Inc | 21823 30th Drive SE, Bothell, Washington (WA) 98021, United States (USA) | Analytical testing | 3002781621028484371 |
| Pfizer Inc | 875 Chesterfield Parkway W, Chesterfield, Missouri (MO) 63017-0774, United States (USA) | Analytical testing, Active ingredient (API) manufacture | 1940118004954111 |
| Pharmacia Hepar LLCRegistrant: Pfizer Inc | 160 Industrial Drive, Franklin, Ohio (OH) 45005, United States (USA) | Analytical testing, Active ingredient (API) manufacture | 1524067030945307 |
| Pharmacia & Upjohn Company LLCRegistrant: Pfizer Inc | 7000 Portage Road, Kalamazoo, Michigan (MI) 49001, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 1810189618054084 |
Alert
Drug shortage listings
82| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Clindamycin Phosphate InjectionAnti-Infective | Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26) | Current | Available | 21 Mar 202321 Sept 2026 |
| Clindamycin Phosphate InjectionAnti-Infective | Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18) | Current | Available | 21 Mar 202321 Sept 2026 |
| Clindamycin Phosphate InjectionAnti-Infective | Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26) | Current | Unavailable | 21 Mar 202321 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50) | Current | Available | 10 Apr 202021 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20) | Current | Available | 10 Apr 202021 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10) | Current | Available | 10 Apr 202021 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12) | Current | Available | 10 Apr 202021 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20) | Current | Available | 10 Apr 202021 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02) | Current | Available | 10 Apr 202021 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20) | Current | Available | 10 Apr 202021 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24) | Current | Available | 10 Apr 202021 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24) | Current | Available | 10 Apr 202021 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01) | Current | Available | 10 Apr 202021 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01) | Current | Available | 10 Apr 202021 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22) | Current | Unavailable | 15 Dec 202121 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52) | Current | Available | 15 Dec 202121 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01) | Current | Available | 15 Dec 202121 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03) | Current | Limited Availability | 15 Dec 202121 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23) | Current | Unavailable | 15 Dec 202121 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01) | Current | Limited Availability | 15 Dec 202121 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02) | Current | Available | 15 Dec 202121 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03) | Current | Limited Availability | 15 Dec 202121 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12) | Current | Available | 15 Dec 202121 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03) | Current | Limited Availability | 15 Dec 202121 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02) | Current | Available | 15 Dec 202121 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51) | Current | Available | 15 Dec 202121 Sept 2026 |
| Methylprednisolone Acetate InjectionRheumatology | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01) | Current | Limited Availability | 15 Dec 202121 Sept 2026 |
| Penicillin G Benzathine InjectionAnti-Infective | Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10) | Current | Unavailable | 26 Apr 202321 Sept 2026 |
| Penicillin G Benzathine InjectionAnti-Infective | Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10) | Current | Limited Availability | 26 Apr 202321 Sept 2026 |
| Penicillin G Benzathine InjectionAnti-Infective | Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10) | Current | Limited Availability | 26 Apr 202321 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10) | Current | Available | 10 Apr 20208 Sept 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02) | Current | Available | 10 Apr 20208 Sept 2026 |
| Clindamycin Phosphate InjectionAnti-Infective | Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04) | Current | Unavailable | 21 Mar 202324 Aug 2026 |
| Clindamycin Phosphate InjectionAnti-Infective | Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02) | Current | Unavailable | 21 Mar 202324 Aug 2026 |
| Clindamycin Phosphate InjectionAnti-Infective | Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06) | Current | Unavailable | 21 Mar 202324 Aug 2026 |
| Dexmedetomidine Hydrochloride InjectionAnesthesia | Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10) | Current | Available | 10 Apr 202024 Aug 2026 |
| Quinapril/Hydrochlorothiazide TabletCardiovascular | Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23) | Current | Unavailable | 19 Jan 202324 Aug 2026 |
| Quinapril/Hydrochlorothiazide TabletCardiovascular | Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23) | Current | Unavailable | 19 Jan 202324 Aug 2026 |
| Quinapril/Hydrochlorothiazide TabletCardiovascular | Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23) | Current | Unavailable | 19 Jan 202324 Aug 2026 |
| Medroxyprogesterone Acetate TabletUrology | PROVERA, Tablet, 10 mg (NDC 0009-0051-01) | To Be Discontinued | - | 31 Aug 202631 Aug 2026 |
| Medroxyprogesterone Acetate TabletUrology | PROVERA, Tablet, 2.5 mg (NDC 0009-0065-01) | To Be Discontinued | - | 31 Aug 202631 Aug 2026 |
| Disopyramide Phosphate Capsule, Extended ReleaseCardiovascular | Norpace CR, Capsule, Extended Release, 150 mg (NDC 0025-2742-31) | To Be Discontinued | - | 24 Aug 202624 Aug 2026 |
| Disopyramide Phosphate Capsule, Extended ReleaseCardiovascular | Norpace CR, Capsule, Extended Release, 100 mg (NDC 0025-2732-31) | To Be Discontinued | - | 24 Aug 202624 Aug 2026 |
| Lorlatinib TabletOncology | Lorbrena, Tablet, 25 mg; 120 tablets bottle with a child-resistant closure (NDC 0069-0227-03) | To Be Discontinued | - | 15 Jun 202615 Jun 2026 |
| Dacomitinib TabletOncology | Vizimpro, Tablet, 45 mg (NDC 0069-2299-30) | To Be Discontinued | - | 8 Jun 20268 Jun 2026 |
| Dacomitinib TabletOncology | Vizimpro, Tablet, 15 mg (NDC 0069-0197-30) | To Be Discontinued | - | 8 Jun 20268 Jun 2026 |
| Dacomitinib TabletOncology | Vizimpro, Tablet, 30 mg (NDC 0069-1198-30) | To Be Discontinued | - | 8 Jun 20268 Jun 2026 |
| Clindamycin Phosphate InjectionAnti-Infective | Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26) | To Be Discontinued | - | 1 Jun 20261 Jun 2026 |
| Clindamycin Phosphate InjectionAnti-Infective | Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC 0009-5095-06) | To Be Discontinued | - | 1 Jun 20261 Jun 2026 |
| Clindamycin Phosphate InjectionAnti-Infective | Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18) | To Be Discontinued | - | 1 Jun 20261 Jun 2026 |
| Clindamycin Phosphate InjectionAnti-Infective | Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26) | To Be Discontinued | - | 1 Jun 20261 Jun 2026 |
| Clindamycin Phosphate InjectionAnti-Infective | Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC 0009-3051-02) | To Be Discontinued | - | 1 Jun 20261 Jun 2026 |
| Clindamycin Phosphate InjectionAnti-Infective | Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04) | To Be Discontinued | - | 1 Jun 20261 Jun 2026 |
| Palbociclib CapsuleOncology | Ibrance, Capsule, 75 mg (NDC 0069-0187-21) | To Be Discontinued | - | 22 Apr 202622 Apr 2026 |
| Palbociclib CapsuleOncology | Ibrance, Capsule, 100 mg (NDC 0069-0188-21) | To Be Discontinued | - | 22 Apr 202622 Apr 2026 |
| Azithromycin TabletAnti-Infective | Zithromax, Tablet, 250 mg (NDC 0069-4061-01) | To Be Discontinued | - | 9 Apr 20269 Apr 2026 |
| Azithromycin TabletAnti-Infective | Zithromax, Tablet, 500 mg (NDC 0069-3070-30) | To Be Discontinued | - | 9 Apr 20269 Apr 2026 |
| Clindamycin Hydrochloride CapsuleAnti-Infective | Cleocin Hydrochloride, Capsule, 75 mg (NDC 0009-0331-02) | To Be Discontinued | - | 25 Feb 202625 Feb 2026 |
| Clindamycin Hydrochloride CapsuleAnti-Infective | Cleocin Hydrochloride, Capsule, 150 mg (NDC 0009-0225-02) | To Be Discontinued | - | 25 Feb 202625 Feb 2026 |
| Clindamycin Hydrochloride CapsuleAnti-Infective | Cleocin Hydrochloride, Capsule, 300 mg (NDC 0009-0395-14) | To Be Discontinued | - | 25 Feb 202625 Feb 2026 |
| Lincomycin Hydrochloride InjectionAnti-Infective | Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04) | To Be Discontinued | - | 25 Feb 202625 Feb 2026 |
| Gemfibrozil TabletEndocrinology/Metabolism | Lopid, Tablet, 600 mg (NDC 0071-0737-20) | To Be Discontinued | - | 10 Feb 202610 Feb 2026 |
| Azithromycin InjectionAnti-Infective | Zithromax IV, Injection, 500 mg/5 mL (NDC 0069-3150-83) | To Be Discontinued | - | 20 Jan 202620 Jan 2026 |
| Spironolactone TabletCardiovascular | Aldactone, Tablet, 100 mg (NDC 0025-1031-31) | To Be Discontinued | - | 10 Dec 202510 Dec 2025 |
| Spironolactone TabletCardiovascular | Aldactone, Tablet, 25 mg (NDC 0025-1001-31) | To Be Discontinued | - | 10 Dec 202510 Dec 2025 |
| Verapamil Hydrochloride InjectionCardiovascular | Verapamil Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-9633-05) | To Be Discontinued | - | 21 Nov 202521 Nov 2025 |
| Ketamine Hydrochloride InjectionAnesthesia | Ketamine Hydrochloride, Injection, 500 mg/5mL (100 mg/mL); Multiple Dose Glass Fliptop Vial Novaplus (NDC 0409-0040-10) | To Be Discontinued | - | 7 Nov 20257 Nov 2025 |
| Voriconazole InjectionAntiviral | Vfend, Injection, 10 mg/1 mL (NDC 0049-3190-01) | To Be Discontinued | - | 16 Oct 202516 Oct 2025 |
| Adalimumab-afzb InjectionRheumatology | Abrilada, Injection, Kit (NDC 0025-0325-01) | To Be Discontinued | - | 9 Oct 20259 Oct 2025 |
| Hydrochlorothiazide; Quinapril Hydrochloride TabletCardiovascular | Accuretic, Tablet, 12.5 mg; 10 mg (NDC 0071-3112-23) | To Be Discontinued | - | 1 Oct 20251 Oct 2025 |
| Hydrochlorothiazide; Quinapril Hydrochloride TabletCardiovascular | Accuretic, Tablet, 12.5 mg; 20 mg (NDC 0071-5212-23) | To Be Discontinued | - | 1 Oct 20251 Oct 2025 |
| Quinapril Hydrochloride TabletCardiovascular | Accupril, Tablet, 10 mg (NDC 0071-0530-23) | To Be Discontinued | - | 1 Oct 20251 Oct 2025 |
| Quinapril Hydrochloride TabletCardiovascular | Accupril, Tablet, 40 mg (NDC 0071-0535-23) | To Be Discontinued | - | 1 Oct 20251 Oct 2025 |
| Quinapril Hydrochloride TabletCardiovascular | Accupril, Tablet, 5 mg (NDC 0071-0527-23) | To Be Discontinued | - | 1 Oct 20251 Oct 2025 |
| Quinapril Hydrochloride TabletCardiovascular | Accupril, Tablet, 20 mg (NDC 0071-0532-23) | To Be Discontinued | - | 1 Oct 20251 Oct 2025 |
| Tafamidis Meglumine CapsuleCardiovascular | Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-1975-40) | To Be Discontinued | - | 29 Sept 202529 Sept 2025 |
| Tafamidis Meglumine CapsuleCardiovascular | Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-8730-30) | To Be Discontinued | - | 29 Sept 202529 Sept 2025 |
| Triazolam TabletPsychiatry | Halcion, Tablet, .25 mg (NDC 0009-0017-58) | To Be Discontinued | - | 29 Sept 202529 Sept 2025 |
| Dobutamine Hydrochloride InjectionCardiovascular, Pediatric, Renal | Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-88) | To Be Discontinued | - | 27 Aug 202527 Aug 2025 |
| Prazosin Hydrochloride CapsuleCardiovascular | Minipress, Capsule, 2 mg (NDC 0069-4370-71) | To Be Discontinued | - | 28 Apr 202328 Apr 2023 |
| Prazosin Hydrochloride CapsuleCardiovascular | Minipress, Capsule, 5 mg (NDC 0069-4380-71) | To Be Discontinued | - | 28 Apr 202328 Apr 2023 |
| Prazosin Hydrochloride CapsuleCardiovascular | Minipress, Capsule, 1 mg (NDC 0069-4310-71) | To Be Discontinued | - | 28 Apr 202328 Apr 2023 |
Catalogue
Drug listings by form and route
2727 active NDC listings: 17 bulk ingredient, 10 drug for further processing. By marketing category: BULK INGREDIENT 17, EXPORT ONLY 10.
| Dosage form | NDCs |
|---|---|
| powder | 16 |
| tablet, film coated | 10 |
| liquid | 1 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| pfizer asia manufacturing pte ltd | 16 |
| pfizer pharmaceuticals llc | 10 |
| pfizer health ab | 1 |
Exclusivity
Patents and exclusivities
174| Patent | Product | Covers | Expiry |
|---|---|---|---|
| RE47739 | IBRANCEpalbociclib | substance, product | Mar 2027 |
| 7807715 | TOVIAZfesoterodine fumarate | product | Jun 2027 |
| 8088398 | TOVIAZfesoterodine fumarate | product | Jun 2027 |
| 8501723 | TOVIAZfesoterodine fumarate | product | Jun 2027 |
| RE47739*PED | IBRANCEpalbociclib | use | Sept 2027 |
| 7807715*PED | TOVIAZfesoterodine fumarate | use | Dec 2027 |
| 8088398*PED | TOVIAZfesoterodine fumarate | use | Dec 2027 |
| 8501723*PED | TOVIAZfesoterodine fumarate | use | Dec 2027 |
| 7815934 | TROXYCA ERnaltrexone hydrochloride; oxycodone hydrochloride | product | Dec 2027 |
| 8431597 | DAURISMOglasdegib maleate | product | Jun 2028 |
| 9126932 | VELSIPITYetrasimod arginine | use | Jul 2029 |
| 10780088 | TALZENNAtalazoparib tosylate | use | Jul 2029 |
| 8012976 | TALZENNAtalazoparib tosylate | substance, product | Jul 2029 |
| 8420650 | TALZENNAtalazoparib tosylate | substance, product | Jul 2029 |
| 9820985 | TALZENNAtalazoparib tosylate | use | Jul 2029 |
| 8580841 | VELSIPITYetrasimod arginine | substance, product | Mar 2030 |
| 10189837 | TALZENNAtalazoparib tosylate | substance, product | Oct 2031 |
| 8735392 | TALZENNAtalazoparib tosylate | substance, product | Oct 2031 |
| 7772243 | VIZIMPROdacomitinib | substance, product | Sept 2032 |
| 8148401 | DAURISMOglasdegib maleate | substance, product | Nov 2032 |
| 8759372 | NURTEC ODTrimegepant sulfate | substance, product | Feb 2033 |
| 8680111 | LORBRENAlorlatinib | substance, product | Mar 2033 |
| 10723730 | IBRANCEpalbociclib | substance, product | Feb 2034 |
| 9545405 | CIBINQOabrocitinib | substance, product | Feb 2034 |
| 9549929 | CIBINQOabrocitinib | use | Feb 2034 |
| 8314117 | NURTEC ODTrimegepant sulfate | substance, product | Feb 2034 |
| 10639309 | XELJANZ XRtofacitinib citrate | product | Mar 2034 |
| 11253523 | XELJANZ XRtofacitinib citrate | use | Mar 2034 |
| 9937181 | XELJANZ XRtofacitinib citrate | product | Mar 2034 |
| 8481546 | ZAVZPRETzavegepant hydrochloride | substance, product | Jun 2034 |
| 10723730*PED | IBRANCEpalbociclib | use | Aug 2034 |
| 10639309*PED | XELJANZ XRtofacitinib citrate | use | Sept 2034 |
| 11253523*PED | XELJANZ XRtofacitinib citrate | use | Sept 2034 |
| 9937181*PED | XELJANZ XRtofacitinib citrate | use | Sept 2034 |
| 12077533 | LITFULOritlecitinib tosylate | use | Dec 2034 |
| 9617258 | LITFULOritlecitinib tosylate | substance, product | Dec 2034 |
| 11007175 | VELSIPITYetrasimod arginine | use | Jan 2036 |
| 12156866 | VELSIPITYetrasimod arginine | use | Jan 2036 |
| 12377071 | VELSIPITYetrasimod arginine | use | Jan 2036 |
| 9035074 | CIBINQOabrocitinib | substance, product | Jan 2036 |
| 10414748 | DAURISMOglasdegib maleate | substance, product | Apr 2036 |
| 11168066 | DAURISMOglasdegib maleate | use | Apr 2036 |
| 11891372 | DAURISMOglasdegib maleate | use | Apr 2036 |
| 10301262 | VELSIPITYetrasimod arginine | substance, product | Jun 2036 |
| 10676435 | VELSIPITYetrasimod arginine | use | Jun 2036 |
| 11091435 | VELSIPITYetrasimod arginine | substance, product | Jun 2036 |
| 11884626 | VELSIPITYetrasimod arginine | use | Jun 2036 |
| 10420749 | LORBRENAlorlatinib | substance, product | Jul 2036 |
| 11020376 | LORBRENAlorlatinib | product | Jul 2036 |
| 11065250 | IBRANCEpalbociclib | product | Aug 2036 |
| 11065250*PED | IBRANCEpalbociclib | use | Feb 2037 |
| 11299500 | LORBRENAlorlatinib | substance | Oct 2038 |
| 11083724 | NURTEC ODTrimegepant sulfate | product | Mar 2039 |
| 11351149 | PAXLOVID (COPACKAGED)nirmatrelvir; ritonavir | substance, product | Aug 2041 |
| 12116368 | LITFULOritlecitinib tosylate | substance | Oct 2041 |
| 11541034 | PAXLOVID (COPACKAGED)nirmatrelvir; ritonavir | use | Oct 2041 |
| Product | Exclusivity | Until |
|---|---|---|
| CIBINQOABROCITINIB | NCE New chemical entity | Jan 2027 |
| IBRANCEPALBOCICLIB | I-995 New indication | Jun 2029 |
| LITFULORITLECITINIB TOSYLATE | NCE New chemical entity | Jun 2028 |
| LORBRENALORLATINIB | ODE-349 Orphan drug | Mar 2028 |
| PAXLOVID (COPACKAGED)NIRMATRELVIR; RITONAVIR | NCE New chemical entity | May 2028 |
| VELSIPITYETRASIMOD ARGININE | NCE New chemical entity | Oct 2028 |
| XELJANZTOFACITINIB CITRATE | PED Paediatric | Aug 2028 |
| ZAVZPRETZAVEGEPANT HYDROCHLORIDE | NCE New chemical entity | Mar 2028 |
Catalogue
Marketed products
27| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | Amlodipine Besylate | powder | 68724-0008BULK INGREDIENT |
| - | Azithromycin Dihydrate | powder | 68724-2124BULK INGREDIENT |
| - | Celecoxib | powder | 68724-1004BULK INGREDIENT |
| - | Crizotinib | powder | 68724-1020BULK INGREDIENT |
| - | Doxasosin Mesylate | powder | 68724-1001BULK INGREDIENT |
| - | Exemestane | powder | 68724-1003BULK INGREDIENT |
| - | Linezolid | powder | 68724-5135BULK INGREDIENT |
| - | Palbociclib | powder | 68724-0187BULK INGREDIENT |
| - | Sertraline hydrochloride | powder | 68724-0011BULK INGREDIENT |
| - | Tafamidis | powder | 68724-8730BULK INGREDIENT |
| - | anakinra | liquid | 87744-234BULK INGREDIENT |
| - | atorvastatin calcium | tablet, film coated | 65427-155EXPORT ONLY |
| - | atorvastatin calcium | tablet, film coated | 65427-156EXPORT ONLY |
| - | atorvastatin calcium | tablet, film coated | 65427-157EXPORT ONLY |
| - | atorvastatin calcium | tablet, film coated | 65427-158EXPORT ONLY |
| - | atorvastatin calcium | tablet, film coated | 65427-255EXPORT ONLY |
| - | atorvastatin calcium | tablet, film coated | 65427-256EXPORT ONLY |
| - | atorvastatin calcium | tablet, film coated | 65427-257EXPORT ONLY |
| - | atorvastatin calcium | tablet, film coated | 65427-258EXPORT ONLY |
| - | azithromycin dihydrate | tablet, film coated | 65427-306EXPORT ONLY |
| - | azithromycin dihydrate | tablet, film coated | 65427-416EXPORT ONLY |
| - | desvenlafaxine succinate | powder | 68724-1236BULK INGREDIENT |
| - | pregabalin | powder | 68724-1235BULK INGREDIENT |
| - | sildenafil citrate | powder | 68724-0025BULK INGREDIENT |
| - | sunitinib malate | powder | 68724-1234BULK INGREDIENT |
| - | tofacitinib citrate | powder | 68724-1000BULK INGREDIENT |
| - | ziprasidone hydrochloride | powder | 68724-5235BULK INGREDIENT |
Neighbours
Registered in the same town
12- Merck & Co., Inc.Singapore, SGP · 5 sites
- Novartis Pharmaceuticals CorporationPuurs-Sint-Amands, BEL; Singapore, SGP · 2 sites
- Baxalta US Inc.Orth an der Donau, AUT; Singapore, SGP · 2 sites
- SanofiSingapore, SGP · 2 sites
- Charles River Laboratories, Inc.Singapore, SGP
- Lonza Biologics IncSingapore, SGP
- AbbVie Inc.Singapore, SGP
- Zoetis IncKalamazoo, MI
- Amgen, IncSingapore, SGP
- Bristol Myers Squibb CompanyBothell, WA
- Genentech, Inc.Singapore, SGP
- AGC Biologics, Inc.Bothell, WA
Compare
Comparable companies in United States
- The Procter & Gamble Manufacturing Company11 sites · 849 NDC
- Zoetis Inc11 sites · 29 NDC
- Sotera Health LLC11 sites · 2 NDC
- Eli Lilly and Company10 sites · 189 NDC
- Siegfried USA, LLC12 sites · 54 NDC
- Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.10 sites · 30 NDC
- Medical-technical Gases, Inc.10 sites · 7 NDC
- SOFIE Co. dba SOFIE12 sites · 5 NDC
- Alcami Carolinas Corporation10 sites · 1 NDC
- AbbVie Inc.13 sites · 131 NDC
Enquiry
Common questions
- Is Pfizer Inc FDA approved?
- Pfizer Inc holds 11 FDA-registered establishments across 8 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Pfizer Inc's drugs manufactured?
- At registered sites in Austria, Belgium, Germany, Ireland, Italy, Singapore and 2 other countries. The FDA register lists Orth an der Donau; Puurs-Sint-Amands; Freiburg im Breisgau; RINGASKIDDY; Ascoli Piceno; Singapore, and 5 more. Registered operations: analytical testing, active ingredient (API) manufacture, labelling, finished drug manufacture, packaging.
- What drugs does Pfizer Inc make?
- 27 products are listed under Pfizer Inc in the openFDA NDC Directory, most often as powder; tablet, film coated; liquid. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
- Are any Pfizer Inc products in shortage?
- 39 presentations are currently listed in the FDA drug shortage database under Pfizer Inc, covering Clindamycin Phosphate Injection, Dexmedetomidine Hydrochloride Injection, Methylprednisolone Acetate Injection and 2 other drugs.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.